IOL Chemicals & Pharmaceuticals is the world’s largest maker of Ibuprofen, the common painkiller, built from a single factory complex in Punjab. It started in 1986 making industrial chemicals, then used that chemistry to move into bulk medicines, adding one dedicated production block after another. The recurring approach is to own every step of the manufacturing chain - from raw chemical intermediates to the finished drug - so it never depends on anyone else for the ingredients that matter most. # Business segments Three engines running on one integrated site - a pharmaceutical anchor built on Ibuprofen, a fast-growing second leg of other essential medicines, and a chemical business that feeds both the drugs and outside customers. ## 1. Ibuprofen and its derivatives: the world’s painkiller factory **IOLCP makes roughly one in every three Ibuprofen molecules sold globally, and it is the only company anywhere that manufactures every chemical building block itself on one campus.** - **Scale nobody else matches** - with an installed capacity of 12,000 tonnes per year and roughly 30-35% of the global market, it is the largest Ibuprofen producer worldwide, running its plant at 85-90% utilisation. - **Backward integration to the root** - it makes Iso Butyl Benzene (IBB), Mono Chloro Acetic Acid (MCA) and Acetyl Chloride in-house, so the entire chain from starter chemicals to finished Ibuprofen, Ibuprofen Sodium and Dex-Ibuprofen sits under one roof. - **Three decades of trust** - the company supplies Ibuprofen to Sanofi and has built a reputation as a reliable long-term partner, which matters because drug regulators are slow to approve new suppliers. - **Cheaper to build, cheaper to run** - it achieved this scale at low capital cost, and its IBB production enjoys a cost advantage of about 15% over China and 35% over Germany, which is why India now commands two-thirds of the global IBB market. ## 2. Non-Ibuprofen APIs: the diversification engine **A portfolio of eight other essential medicines - led by Paracetamol and Metformin - that has grown from under a fifth of the pharma business to over a third, using the same playbook of dedicated plants and self-made raw materials.** - **Paracetamol, fully home-made** - a new automated plant with 10,800 tonnes of annual capacity was commissioned in 2025, adding to the existing capacity, and it is fed by in-house production of the key intermediate PAP and Acetic Anhydride. - **Metformin on a dedicated line** - with 7,200 tonnes of annual capacity, it is among India’s largest producers, and a block conversion is underway to push output to 950 tonnes a month. - **A clutch of niche drugs** - dedicated facilities also make Clopidogrel (a blood thinner, 240 tonnes), Pantoprazole (an acid-reflux drug, 276 tonnes), and multi-product plants handle Fenofibrate, Levetiracetam, Lamotrigine and Losartan. - **Regulatory doors already open** - the factory holds USFDA approval, EU GMP certification, and in 2024 all ten API units were cleared by Brazil’s ANVISA, which lets the company sell into regulated markets where prices are 10-20% higher. ## 3. Specialty chemicals: the feedstock engine that also pays its own way **A set of industrial chemicals that serve as the raw-material backbone for the drug business while also being sold to paint, packaging, food and pesticide makers - with Ethyl Acetate as the single-biggest product.** - **India’s largest single-site Ethyl Acetate maker** - capacity stands at 120,000 tonnes per year, all sold to outside customers in over 40 countries, and the product is REACH-certified for the European Union. - **The Ibuprofen supply chain, monetised** - IBB (12,000 tonnes capacity, about 30% global share) and Acetic Anhydride (32,000 tonnes) are sold to the market as well as consumed captively, so the plant earns revenue from its own raw-material chain. - **Green chemistry recognised** - the MCA and Acetyl Chloride plant runs on Asia’s first continuous dual-technology process and won a National Award for Technology Innovation from the Indian government. - **A new addition in Triacetin** - a 6,000-tonne plant commissioned in 2026 strengthens the integration further and adds another merchant product to the portfolio. # Manufacturing and sustainability backbone **Everything happens on a single 180-acre site with its own power, steam, water treatment and R&D - a self-contained industrial city that runs on rice husks and sunlight.** - **One campus, eleven dedicated units** - the Barnala site houses 16 commercial manufacturing facilities including multi-product blocks, with steam generation of 185 tonnes per hour and temperature control from -20°C to 275°C. - **Power from crop waste** - a 17 MW co-generation plant burns rice husk (biofuel) to meet power and steam needs, with 80% of electricity now coming from renewable sources and solar panels adding 1,187 KW. - **No liquid waste leaves the site** - a zero-liquid-discharge plant treats all effluent, solvent recovery runs alongside, and the company is water-neutral with a green belt covering over a third of the premises. - **A 120-strong R&D team on the factory floor** - the DSIR-approved lab works on continuous flow chemistry and enzymes to replace metal-based reactions, and files five to six US drug master files every year. # Group structure and partners **A standalone operating company with a handful of small, mostly dormant subsidiaries - no holding company, no joint ventures, and the founding family still holding a significant stake.** - **The listed entity is the operating company** - IOL Chemicals & Pharmaceuticals Ltd has no parent or associate company, and its promoters held about 44% of the equity as of FY21. - **Subsidiaries are small and largely inactive** - IOL Foundation handles CSR, while IOL Life Sciences, IOL Speciality Chemicals and the newly incorporated UK entity IOL Pharmaxis UK had not commenced business as of their respective incorporation dates. - **One related-party supplier** - Vivachem Intermediates, a firm controlled by key management, transacts with the company for raw-material purchases and goods in the ordinary course of business.